FOSTER CITY, Calif.--(BUSINESS WIRE)--Dec. 15, 2014--
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Philippe C.
Bishop, MD, will join the company as Senior Vice President, Hematology
and Oncology Therapeutics. In this position, Dr. Bishop will report to
John McHutchison, MD, Executive Vice President, Clinical Research and
will have responsibility for Gilead’s programs in oncology. Dr. Bishop
will also join Gilead’s Executive Committee.
“Philippe is an accomplished physician with an extensive background in
cancer drug development and I am very pleased to welcome him to Gilead,”
said Dr. McHutchison. “Philippe’s appointment reflects Gilead’s ongoing
commitment to further building a leading hematology and oncology
therapeutic area. His clinical development expertise, translational
focus and strategic leadership will be of great value as we work to
advance our growing pipeline of therapies for hematological malignancies
and solid tumors.”
Dr. Bishop joins Gilead from Genentech, where he has served as Vice
President, Product Development, Oncology since 2007. At Genentech, he
was responsible for the development of Avastin, contributed to many of
the company’s oncology pipeline therapeutics and was a member of the
Roche/Genentech joint leadership team. Prior to joining Genentech, Dr.
Bishop led efforts to develop cancer therapies at Johnson & Johnson and
Sanofi-Aventis. Dr. Bishop also previously held positions at the U.S.
Food and Drug Administration (FDA) and the National Institutes of Health
(NIH).
“Over the last several years, Gilead has worked to build strong
expertise and an extensive pipeline within the hematology and oncology
areas,” said Dr. Bishop. “I am excited to join this dedicated,
scientifically focused team, which shares my commitment and passion for
scientific innovation, and I look forward to working with them to bring
new therapeutic options to people living with cancer.”
Dr. Bishop received his undergraduate degree from Loyola Marymount
University in Los Angeles and his medical degree from the University of
Nevada School of Medicine. He completed training in internal medicine at
the University of Washington School of Medicine and a medical oncology
fellowship at the National Cancer Institute (NCI).
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops
and commercializes innovative therapeutics in areas of unmet medical
need. The company’s mission is to advance the care of patients suffering
from life-threatening diseases. Gilead has operations in more than 30
countries worldwide, with headquarters in Foster City, California.
For more information on Gilead Sciences, please visit the company’s
website at www.gilead.com,
follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs
at 1-800-GILEAD-5 or 1-650-574-3000.
Source: Gilead Sciences, Inc.
Gilead Sciences, Inc.Patrick O’Brien, 650-522-1936 (Investors)Amy
Flood, 650-522-5643 (Media)
